Although eculizumab, a C5-targeted complement blocker, is very promise in prophylaxis and treatment for recurrent aHUS after kidney transplantation [33,34], it was not a therapeutic option in our cohort, since, in Brazil's publicly funded health care system, it is only available for treatment of patients with paroxysmal nocturnal hemoglobinuria (PNH). Here, C5 is linked to paroxysmal nocturnal hemoglobinuria.